Showing results (251-260 of 322) with videos related to
Sort By:
Pageof 33
Pharmacology Research & Perspectives|August 7, 2019
Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2Paul Oranje, Robin Gouka, Lindsey Burggraaff, et al.Journal of Medicinal Chemistry|September 14, 2013
Structure-kinetic relationships--an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as chemokine receptor 2 antagonistsMaris Vilums, Annelien J M Zweemer, Zhiyi Yu, et al.Journal of Medicinal Chemistry|July 14, 2017
Discovery and Kinetic Profiling of 7-Aryl-1,2,4-triazolo[4,3-a]pyridines: Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2Maarten L J Doornbos, José María Cid, Jordi Haubrich, et al.European Journal of Medicinal Chemistry|February 11, 2015
When structure-affinity relationships meet structure-kinetics relationships: 3-((Inden-1-yl)amino)-1-isopropyl-cyclopentane-1-carboxamides as CCR2 antagonistsMaris Vilums, Annelien J M Zweemer, Farhana Barmare, et al.ACS Chemical Biology|August 26, 2024
Labeling of CC Chemokine Receptor 2 with a Versatile Intracellular Allosteric ProbeLisa S den Hollander, Bert L H Beerkens, Sebastian Dekkers, et al.Nature Communications|October 4, 2017
Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptorsDavid A Sykes, Holly Moore, Lisa Stott, et al.Molecular Pharmacology|September 12, 2013
Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptorsJ Robert Lane, Pavel Chubukov, Wei Liu, et al.Neuropharmacology|March 9, 2026
Differential inhibition of the diverse behavioural effects of mu-opioid receptor agonists by progressive receptor depletionLauren Brown, Cory Langreck, Frances Hough, et al.Journal of Medicinal Chemistry|June 9, 2015
Structure-activity study of N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652), a bitopic ligand that acts as a negative allosteric modulator of the dopamine D2 receptorJeremy Shonberg, Christopher Draper-Joyce, Shailesh N Mistry, et al.Molecular Pharmacology|June 27, 2013
Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M₁ muscarinic acetylcholine receptorPeter Keov, Celine Valant, Shane M Devine, et al.Pageof 33